Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...

Azacitidine (Vidaza, Celgene) is standard treatment for patients with myelodysplastic syndrome (MDS) and will remain the treatment of choice — at least for now. A new study that tested two different ...

The phase 3 trial for high-risk MDS with RARA overexpression did not achieve its primary endpoint of CR rate. Tamibarotene-Vidaza treatment showed a 23.8% CR rate, not significantly different from the ...

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The ...

(WASHINGTON – August 6, 2025) – Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results ...

Hypomethylating agents (HMAs) are underutilized in high-risk MDS patients, especially among older, female, and non-White individuals. Only 16.1% of Medicare patients with newly diagnosed MDS received ...

Medical experts discuss risk-based approaches to choosing MDS therapies. Provide a high level overview of treatment approaches for both lower and higher risk MDS. What are the key considerations when ...